Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.

[1]  H. Dombret,et al.  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.

[2]  A. Yang,et al.  Evaluating new treatment options for MDS. , 2007, Clinical advances in hematology & oncology : H&O.

[3]  G. Garcia-Manero.  Recent Advances in the Treatment of MDS. A review of selected presentations from the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, Florida. , 2007, Clinical advances in hematology & oncology : H&O.

[4]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[5]  P. Fenaux,et al.  A non‐randomised dose‐escalating phase II study of thalidomide for the treatment of patients with low‐risk myelodysplastic syndromes: the Thal‐SMD‐2000 trial of the Groupe Français des Myélodysplasies , 2005, British journal of haematology.

[6]  F. Lanza,et al.  Darbepoetin alpha for the treatment of anaemia in low‐intermediate risk myelodysplastic syndromes , 2005, British journal of haematology.

[7]  P. Musto.  Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. , 2004, Leukemia research.

[8]  M. Bisceglia,et al.  Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. , 2002, Haematologica.

[9]  U. Germing,et al.  Thalidomide for the treatment of patients with myelodysplastic syndromes , 2002, Leukemia.

[10]  P. Venugopal,et al.  The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes , 2001, British journal of haematology.

[11]  P. Venugopal,et al.  Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. , 2001, Blood.

[12]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[13]  P. Greenberg,et al.  Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model , 1997, British journal of haematology.

[14]  L. Lessin,et al.  The use of r‐HuEpo in the treatment of anaemia related to myelodysplasia (MDS) , 1995, British journal of haematology.